Oral small molecule GLP-1 receptor agonist
HRS-7535 tablet
HRS7535_PO
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.42 (0.00 to 31.28) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.40 (1.03 to 6.15) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.43 (0.53 to 15.12) | 0.34 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 2.21 (0.58 to 11.77) | 0.21 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.93 (0.54 to 157) | 0.20 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.90 (2.69 to 37.84) | 0.10 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.21 (1.42 to 23.68) | 0.24 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.40 (1.06 to 13.71) | 0.19 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.68 (0.05 to 10.25) | 0.44 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -1.87 (-13.76 to 9.61) | 0.43 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.83 (-10.25 to 3.29) | 0.33 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -3.60 (-10.51 to 3.51) | 0.32 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.47 (0.26 to 13.94) | 0.48 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.15 (0.40 to 112) | 0.35 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 9.70 (3.04 to 46.72) | 0.16 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 13.83 (3.19 to 104) | 0.21 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.64 (0.87 to 8.94) | 0.36 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.45 (0.42 to 115) | 0.30 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.07 (0.14 to 78.04) | 0.48 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 2.21 (0.40 to 16.37) | 0.26 |
| Chronic kidney disease with diabetes | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.80 (0.53 to 134) | 0.23 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 8.67 (1.88 to 38.63) | 0.11 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 5.06 (1.11 to 24.82) | 0.38 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 3.30 (0.75 to 16.91) | 0.38 |
Trials
- SOLID-DKDA Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Diabetic Kidney Disease in Type 2 Diabetes2024 · 281 randomized · 16 weeks
- NCT06250946A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects2024 · 235 randomized · 36 weeks